Senator Calls on Federal Health Authorities to Review Chinas Role in US Drug Trials

Sen. Rick Scott (R-Fla.) speaks during a press conference in the U.S. Capitol in Washington on July 11, 2023. Madalina Vasiliu/The Epoch TimesSenate Committee on Aging Chairman Sen. Rick Scott (R-Fla.) is raising concerns over Chinese entities participating in U.S. clinical trials and drug approval processes and calling for immediate action from federal health agencies.In a March 19 letter to federal health authorities, shared with The Epoch Times beforehand, Scott pointed to Bioheng, a China-based clinical-stage company also known as Imviva, as being “reportedly financed by [Chinese Communist Party]-linked sources.”